Bionano Genomics, Inc.

BNGO Nasdaq SEC CIK 1411690
Follow Bionano Genomics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $8.3M +12.3% vs same quarter last year
Net income −$6.5M +24.1% vs same quarter last year
EPS, diluted −$0.54 +66% vs same quarter last year
Operating cash flow −$4.5M +23.6% vs same quarter last year
Revenue by quarter
$8.2M
$6.5M
$6.7M
$7.4M
$8M
$6.7M
$8.2M
$8.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$28.5M−$26.4M
FY24$30.8M−$112M
FY23$36.1M−$232.5M
FY22$27.8M−$132.6M
FY21$18M−$72.4M
FY20$8.5M−$41.1M
FY19$10.1M−$29.8M
FY18$12M−$18.5M
FY17$9.5M−$23.4M
FY16--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−800%−600%−400%−200%0%200%FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2546.3%−116.9%−92.6%
FY241.2%−337.9%−364%
FY2326.5%−596%−643.7%
FY2221.4%−473.7%−476.9%
FY2121.5%−428.8%−402.8%
FY2032.6%−453.4%−483.4%
FY1933.2%−255.4%−294.3%
FY1827.4%−170.1%−154.1%
FY1736.6%−244.3%−245.8%
FY16---
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21-
FY20−$38.3M
FY19−$29.6M
FY18−$20.3M
FY17−$21.8M
FY16-
Net margin vs the sectorMedian of Technology companies filing with the SEC
  • Bionano Genomics
  • Technology median
−800%−600%−400%−200%0%200%FY17FY19FY21FY23FY25
Show the numbers
YearBionano GenomicsTechnology median
FY25−92.6%−2.4%
FY24−364%−5%
FY23−643.7%−6.7%
FY22−476.9%−4.4%
FY21−402.8%−1.7%
FY20−483.4%−3%
FY19−294.3%0%
FY18−154.1%0.8%
FY17−245.8%2%
FY16-2.3%